Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431910 | 1.00 | PLA2G1B (0.57) | PLA2G1BATG4BNPC1CA12CA1 | |
| SCHEMBL14183973 | 0.87 | PLA2G1B (0.62) | PLA2G1BATG4BNPC1CA12CA1 | |
| SCHEMBL19449477 | 0.85 | HPGD (0.67) | PLA2G1BATG4BNPC1CA12CA1 | |
| SCHEMBL4929420 | 0.84 | HPGD (0.53) | NPC1CA12CA1CA2ALDH1A1 | |
| SCHEMBL13487932 | 0.83 | NPC1 (0.63) | PLA2G1BATG4BNPC1CA12CA1 | |
| SCHEMBL6432230 | 0.82 | HPGD (0.60) | PLA2G1BATG4BALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4788083 | 0.82 | HPGD (0.60) | PLA2G1BATG4BALDH1A1GAASMN1; SMN2 | |
| SCHEMBL5330912 | 0.80 | PLA2G1B (0.61) | PLA2G1BATG4BNPC1CA12CA1 | |
| SCHEMBL17152273 | 0.80 | ALDH1A1 (0.49) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL3240749 | 0.79 | LMNA (0.55) | ALDH1A1RAB9AGAASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| EP-0813868-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6538006-B1 | N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, methods for making the compounds, and intermediates useful in the method. Also, a method for inhibiting retroviral proteases and for treatment of | PHARMACIA CORPORATION | 2003-03-25 | — | — | US | disclosed |
| EP-0735019-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2000-09-20 | — | — | EP | disclosed |
| EP-0558603-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-08-26 | — | — | EP | disclosed |
| EP-0558630-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5708004-A | ENZYME INHIBITORS FOR TREATMENT OF AIDS | MONSANTO COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0815856-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5703076-A | TREATING HIV, AIDS | G. D. SEARLE & CO. (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040974-A1 | Retroviral protease inhibitors | PREP, TMPRSS15, DNPEP | PLA2G1B 3188/4885ATG4B 141/4885NPC1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.